Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

Clinical trial NCT03110380 · COMPLETED

Trial details

NCT number: NCT03110380
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV-1-infection

Start date: 2017-06-12
Primary completion: 2018-12-04
Enrollment: 567

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.